Generic Name and Formulations:
Desmopressin acetate 0.83mcg, 1.66mcg; per nasal spray; preservative-free.
Indications for NOCTIVA:
Nocturia due to nocturnal polyuria in adults who awaken ≥2 times per night to void.
Limitations Of use:
Not studied in patients <50yrs of age.
<65yrs (without increased risk of hyponatremia): 1 spray (1.66mcg) in either nostril approx. 30mins before bedtime. ≥65yrs (or <65yrs with increased risk of hyponatremia): initially 1 spray (0.83mcg) in either nostril approx. 30mins before bedtime; may increase to 1.66mcg after ≥7 days, if needed, provided the serum sodium has remained normal.
Hyponatremia, or history of. Polydipsia. Primary nocturnal enuresis. Concomitant loop diuretics, systemic or inhaled glucocorticoids. Renal impairment (eGFR <50mL/min/1.73m2). Known or suspected SIADH secretion. During illnesses that can cause fluid/electrolyte imbalance (eg, gastroenteritis, salt-wasting nephropathies, or systemic infection). CHF (NYHA Class II–IV). Uncontrolled hypertension.
Evaluate and confirm diagnosis with 24-hr urine collection prior to initiation. Risk of hyponatremia (may be severe). Monitor serum sodium levels prior to initiating or resuming dose, within 7 days and approx. 1 month after starting or increasing dose, and periodically thereafter. Monitor more frequently for elderly (≥65yrs) or those on concomitant drugs that can increase the risk of hyponatremia. Interrupt or permanently discontinue if hyponatremia occurs; treat appropriately. CHF (NYHA Class I): monitor volume status. Risk of increased intracranial pressure, history of urinary retention: not recommended. Discontinue if concurrent nasal conditions (eg, nasal mucosa atrophy, acute/chronic rhinitis) that may increase absorption, until resolved. Pregnancy: not recommended. Nursing mothers.
See Contraindications. May start or resume Noctiva 3 days or 5 half-lives after glucocorticoid is discontinued (whichever is longer). Concomitant medications that may cause water retention or increase hyponatremia risk (eg, tricyclics, SSRIs, NSAIDs, opioids, chlorpromazine, carbamazepine, lamotrigine, thiazides): monitor serum sodium more frequently. Concomitant other intranasal drugs: not recommended.
Nasal discomfort, nasopharyngitis, nasal congestion, sneezing, hypertension/BP increased, back pain, epistaxis, bronchitis, dizziness; hyponatremia, fluid retention.
Nasal spray—3.5mL (30 sprays)
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Oxidized Low-Density Lipoprotein May Predict Risk for Recurrent Stroke
- Inappropriate Prescribing Protocols in Parkinson Disease
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Congress Passes Bill to Fight Opioid Crisis